A5011260402- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Lung Cancer Research Studies
- Genomics and Chromatin Dynamics
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Cell Image Analysis Techniques
- RNA modifications and cancer
- Glioma Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Brain Metastases and Treatment
- Hedgehog Signaling Pathway Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
Boston University
2025
Dana-Farber Cancer Institute
2025
Harvard University
2024-2025
Virginia Commonwealth University
2021-2024
University of Richmond
2021-2023
VCU Massey Comprehensive Cancer Center
2021
Virginia Cancer Institute
2021
Abstract Changes in the three-dimensional (3D) structure of genome are an emerging hallmark cancer. Cancer-associated copy number variants and single nucleotide polymorphisms promote rewiring chromatin loops, disruption topologically associating domains (TADs), active/inactive state switching, leading to oncogene expression silencing tumor suppressors. However, little is known about 3D changes during cancer progression a chemotherapy-resistant state. We integrated conformation capture...
Article15 February 2021Open Access Source DataTransparent process Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies Tanmoy Mondal Laboratory of Novel Biologics, University Virginia, Charlottesville, VA, USA Department Biochemistry Molecular Genetics, Search for more papers this author Gururaj N Shivange Rachisan GT Tihagam Evan Lyerly Undergraduate Research Program, Michael Battista Divpriya Talwar Roxanna Mosavian Karol Urbanek...
An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15-20% have basal-like triple-negative (TNBC), which is known to highly metastatic. Chemotherapy standard of care for TNBC patients, but chemoresistance a common clinical problem. There currently lack alternative, targeted treatment strategies TNBC; this study sought identify novel therapeutic combinations treat TNBCs. For studies, four human cell lines were utilized determine the cytotoxicity...
Abstract The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development resistance epidermal growth factor receptor inhibitors (EGFRi) and drugs are cytotoxic once EGFRi occurs. Human patient-derived xenografts (PDXs) grown immunodeficient mice treated with a set EGFRi; erlotinib was selected for more expansive vivo studies. Single-cell RNA sequencing performed on mammary tumors from PDX WHIM2 vehicle or 9 weeks. then...
Abstract Changes in the three-dimensional (3D) structure of genome are an emerging hallmark cancer. Cancer-associated copy number variants and single nucleotide polymorphisms promote rewiring chromatin loops, disruption topologically associating domains (TADs), active/inactive state switching, leading to oncogene expression silencing tumor suppressors. However, little is known about 3D changes during cancer progression a chemotherapy-resistant state. We integrated conformation capture...
Abstract Breast cancers that are hormone receptor negative, such they do not express the estrogen (ER), progesterone (PR), or human epidermal growth factor 2 (HER2), known as triple-negative breast cancer (TNBC), and predominantly of basal-like subtype. These tumors aggressively metastasize, have limited effective therapeutic options, prevalent in patients African descent. In these studies, we utilized a racially diverse set 21 patient-derived xenografts (PDXs) 6 cell lines to identify new...